Celgene (CELG) Tops Q2 EPS by 4c, Raise FY EPS Guiadnce

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Celgene (CELG) Tops Q2 EPS by 4c, Raise FY EPS Guiadnce

Celgene Reports Second Quarter 2017 Operating and Financial Results

July 27, 2017 7:30 AM EDT

- Strong Q2 performance; Updated 2017 EPS guidance

- Positive ozanimod phase III data in relapsing multiple sclerosis (RMS) advances neuroscience franchise opportunities

- Completed enrollment in five phase III trials during Q2, with data expected in 2018; Multiple phase III data readouts expected in H2:17

- BGB-A317 (PD-1 inhibitor) transaction accelerates immuno-oncology strategy in solid tumors

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $3,256 million for the second quarter of 2017, a 19 percent increase from... More